Just Published: "Kenya Pharmaceuticals & Healthcare Report Q1 2015"

From: Fast Market Research, Inc.
Published: Fri Nov 14 2014

The rising non-communicable disease burden will boost demand for prescription medicines to treat chronic diseases in Kenya. However, we believe drugmakers cannot employ their developed state business models to market medicines in a country that has traditionally focussed on the treatment of infectious diseases such as malaria, tuberculosis and HIV. Besides challenges related to diagnosis, care and treatment, there is a lack of understanding and knowledge about diseases such as diabetes and cancer among healthcare professionals and the general population, and a perception that these diseases are not as critical as other s affecting the country. Furthermore, limited government contribution to healthcare and low affordability levels create the need to establish structured channels through which companies can boost the use of their products - particularly as in an emerging market like Kenya, the demand for medicines is not equal to the uptake of medicines.

Full Report Details at
- http://www.fastmr.com/prod/900721_kenya_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=303

Headline Expenditure Projections

* Pharmaceuticals: KES55.29bn (USD642mn) in 2013 to KES63.77bn (USD725mn) in 2014; 15.3% growth in local currency terms and 12.9% in US dollar terms.
* Healthcare: KES184.28bn (USD2.14bn) in 2013 to KES207.59bn (USD2.36bn) in 2014; 12.6% growth in local currency terms and 10.2% in US dollar terms.

Risk/Reward Index

In BMI's Q115 Pharmaceutical and Healthcare Risk/Reward Index (RRIs), Kenya is 18th in the Middle East and Africa (MEA) region. A large counterfeit drug industry, poor healthcare funding, corruption, regulatory deficiencies and a number of other issues will conspire to keep Kenya in a low position in the MEA matrix. Nevertheless, in comparison with many other African markets, most of which are not surveyed by BMI, Kenya offers greater commercial promise and a more stable overall business environment.

Key Trends And Developments

In October 2014, the Kenyan Ministry of Health stated that it would press for information on the ongoing international...

The Kenya Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kenya Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kenyan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Kenya to test other views - a key input for successful budgeting and strategic business planning in the Kenyan pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
- Thailand Pharmaceuticals & Healthcare Report Q1 2015
- Hong Kong Pharmaceuticals & Healthcare Report Q1 2015
- Croatia Pharmaceuticals & Healthcare Report Q1 2015
- Singapore Pharmaceuticals & Healthcare Report Q4 2014

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »